NCT04796922
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) treatment 3 withdrawn NCT04431089
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma No drug interventions treatment 2 unknown_status NCT00877214
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas No drug interventions treatment 3 active_not_recruiting NCT00991211
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab No drug interventions treatment 3 completed NCT02650999
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas No drug interventions treatment 1 / 2 completed NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 completed NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies No drug interventions treatment 1 completed NCT03636503
RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA No drug interventions treatment 1 active_not_recruiting NCT02536664
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants No drug interventions Not Available Not Available completed NCT04989621
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) No drug interventions treatment 2 unknown_status NCT01460602
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma No drug interventions treatment 1 / 2 withdrawn NCT03436602
Personalized Risk Stratification Model of Follicular Lymphoma Patients No drug interventions Not Available Not Available active_not_recruiting NCT04792502
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma No drug interventions treatment 2 recruiting NCT01662102
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) No drug interventions treatment 3 terminated NCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) No drug interventions Not Available Not Available not_yet_recruiting NCT00634179
A Phase I/II Trial of VR-CHOP in Lymphoma Patients No drug interventions treatment 1 / 2 completed NCT03806179
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL No drug interventions treatment 1 completed NCT01306643
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma No drug interventions treatment 1 / 2 completed NCT01303887
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients treatment 3 unknown_status NCT01980654
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma treatment 2 completed NCT05255354
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy No drug interventions Not Available Not Available recruiting NCT04849351
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma No drug interventions treatment 2 recruiting NCT03121677
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma treatment 1 terminated NCT02947347
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma treatment 3 active_not_recruiting NCT02756247
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma treatment 1 completed NCT04508647
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma treatment 2 completed NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. No drug interventions treatment 1 recruiting NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT02978898
CD180 Overexpression in Follicular Lymphoma No drug interventions Not Available Not Available completed NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT05934097
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma treatment 1 withdrawn NCT03999697
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies No drug interventions treatment 1 unknown_status NCT02793583
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma treatment 2 / 3 terminated NCT03568461
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma treatment 2 active_not_recruiting NCT06510361
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a Complete Response With Upfront Chemoimmunotherapy treatment 2 not_yet_recruiting NCT03190928
Clonal Evolution in Follicular Lymphoma No drug interventions Not Available Not Available recruiting NCT04154228
Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI No drug interventions diagnostic Not Available unknown_status NCT00384111
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) No drug interventions treatment 3 terminated NCT01313611
BRIEF Bendamustine and Rituximab In Elderly Follicular treatment 2 terminated NCT04224493
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. treatment 3 recruiting NCT03980171
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma treatment 1 / 2 active_not_recruiting NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product No drug interventions Not Available Not Available terminated NCT01597778
Double Cord Versus Haploidentical (BMT CTN 1101) No drug interventions treatment 3 completed NCT04587388
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry No drug interventions Not Available Not Available recruiting NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT00440388
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease No drug interventions treatment 2 active_not_recruiting NCT05783609
Epcoritamab and Rituximab for First-line Follicular Lymphoma treatment 2 recruiting NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35 treatment 2 terminated NCT03715309
R2 in the Treatment of Follicular Lymphoma treatment 2 unknown_status NCT01275209
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma treatment 1 completed NCT04034056
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) Not Available Not Available completed NCT06049485
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research No drug interventions Not Available Not Available not_yet_recruiting NCT00901615
Lenalidomide and R-CHOP in B-cell Lymphoma treatment 1 / 2 completed NCT05784415
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell No drug interventions Not Available Not Available active_not_recruiting NCT03374137
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Not Available Not Available completed NCT06492837
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients treatment 2 not_yet_recruiting NCT06340737
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas No drug interventions treatment 1 recruiting NCT06108232
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma treatment 2 recruiting NCT03361852
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma treatment 1 active_not_recruiting NCT04680052
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. treatment 3 active_not_recruiting NCT06553352
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma treatment 2 recruiting NCT02449252
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma treatment 3 recruiting NCT02536300
Dose Optimization Study of Idelalisib in Follicular Lymphoma treatment 3 terminated NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT03919175
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma treatment 2 terminated NCT00366275
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 completed NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT01939899
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma treatment 2 completed NCT02008006
BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) treatment 2 terminated NCT05749549
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers No drug interventions treatment 1 / 2 active_not_recruiting NCT04082936
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT05551936
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma treatment 1 / 2 recruiting NCT04176913
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 terminated NCT04842318
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study No drug interventions treatment 4 unknown_status NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas treatment 2 recruiting NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab treatment 1 / 2 active_not_recruiting NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma treatment 1 recruiting NCT02303119
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) treatment 3 completed NCT05003141
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies No drug interventions treatment 1 unknown_status NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities treatment 2 not_yet_recruiting NCT02791217
Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool No drug interventions Not Available Not Available unknown_status NCT04599634
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies treatment 1 completed NCT05387616
A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden treatment 2 active_not_recruiting NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT03842696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation prevention 1 / 2 recruiting NCT00085696
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma treatment 2 completed NCT05621096
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT01151358
Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy No drug interventions Not Available Not Available unknown_status NCT05994235
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma treatment 2 recruiting NCT06549335
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients With Follicular Lymphoma (FL) treatment 2 not_yet_recruiting NCT00696735
High-Dose Therapy Treatment in Patients With Follicular Lymphoma No drug interventions treatment 3 completed NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT02213263
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) treatment 3 completed NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib) treatment 3 enrolling_by_invitation NCT01926639
Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma treatment 2 completed NCT05444322
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma No drug interventions treatment 0 recruiting NCT02295722
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma treatment 1 / 2 terminated NCT06284122
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 treatment 3 recruiting NCT05284825
A Phase II Trial of Intermediate Radiation Dose For Lymphoma No drug interventions treatment Not Available recruiting NCT04934930
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status treatment 2 recruiting NCT05867030
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma treatment 1 withdrawn NCT02401048
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas treatment 1 / 2 completed NCT03221348
A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma No drug interventions treatment 1 unknown_status NCT00907348
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma No drug interventions treatment 2 unknown_status NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) treatment 1 active_not_recruiting NCT03069248
Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon treatment 2 completed NCT01120457
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers treatment 1 completed NCT04323657
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT03151057
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies treatment 1 terminated NCT03720457
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. No drug interventions treatment 1 unknown_status NCT01121757
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma treatment 2 terminated NCT04962126
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy treatment 2 active_not_recruiting NCT03019666
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL treatment 1 completed NCT01419665
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) treatment 3 completed NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT03520920
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) treatment 2 completed NCT02204982
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma treatment 3 terminated NCT00140582
Primary Rituximab and Maintenance treatment 3 completed NCT03010982
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors treatment 1 completed NCT04762160
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma treatment 2 terminated NCT00096460
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) treatment 2 / 3 terminated NCT01370694
Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) treatment 1 terminated NCT01130194
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma No drug interventions treatment 2 completed NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT05414162
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy No drug interventions Not Available Not Available recruiting NCT03135262
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) treatment 1 / 2 terminated NCT01446562
Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma treatment 2 completed NCT05665062
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies treatment 1 recruiting NCT06151080
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL treatment 2 recruiting NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. treatment 1 recruiting NCT03890289
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma treatment 2 terminated NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT00636792
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 completed NCT05020392
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma No drug interventions treatment 3 recruiting NCT01953692
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) No drug interventions treatment 1 completed NCT04305444
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas No drug interventions treatment 2 active_not_recruiting NCT00530140
Idiotypic Vaccination for Follicular Lymphoma Patients No drug interventions treatment 2 unknown_status NCT03234140
Constitutional Genetics in Follicular Lymphoma No drug interventions Not Available Not Available unknown_status NCT04379167
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma No drug interventions treatment 2 unknown_status NCT01650701
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma No drug interventions treatment 3 active_not_recruiting NCT03178201
TGR1202 in Relapsed and Refractory Follicular Lymphoma No drug interventions treatment 2 terminated NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies No drug interventions treatment 1 / 2 withdrawn NCT03676504
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR No drug interventions treatment 1 / 2 recruiting NCT05058404
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma No drug interventions treatment 3 recruiting NCT00001572
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype treatment 1 completed NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep No drug interventions treatment 2 active_not_recruiting NCT03381768
Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma No drug interventions treatment 1 completed NCT03276468
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas No drug interventions treatment 2 completed NCT01180569
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma No drug interventions treatment 1 / 2 withdrawn NCT00140569
Randomized Study for Patients With Follicular Lymphoma Needing Treatment treatment 3 completed NCT00992446
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma No drug interventions treatment 2 completed NCT02315612
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies No drug interventions treatment 1 active_not_recruiting NCT06068881
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation No drug interventions treatment 2 not_yet_recruiting NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomas No drug interventions treatment 2 completed NCT00772655
Zevalin® First Line in Follicular Lymphoma No drug interventions treatment 2 unknown_status NCT02677155
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma No drug interventions treatment 2 completed NCT06339255
Italian Observational Study on CAR-T Therapy for Lymphoma No drug interventions Not Available Not Available recruiting NCT00794638
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT04503538
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity No drug interventions supportive_care Not Available withdrawn NCT02461290
Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1 No drug interventions Not Available Not Available completed NCT05512390
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 recruiting NCT03245021
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A No drug interventions treatment 1 active_not_recruiting NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation No drug interventions treatment 2 active_not_recruiting NCT05899621
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL No drug interventions Not Available Not Available recruiting NCT03976102
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma No drug interventions treatment 3 completed NCT01493479
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma No drug interventions treatment 2 completed NCT04707079
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma No drug interventions treatment 2 unknown_status NCT06424379
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. No drug interventions Not Available Not Available active_not_recruiting NCT05064787
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy No drug interventions supportive_care Not Available completed NCT01476787
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma No drug interventions treatment 3 completed NCT01329354
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy No drug interventions treatment 2 unknown_status NCT02194751
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT05611853
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies No drug interventions treatment 1 / 2 terminated NCT06112847
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma No drug interventions treatment 2 recruiting NCT04663347
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) No drug interventions treatment 1 / 2 recruiting NCT01118845
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma No drug interventions treatment 2 completed NCT02242045
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 completed NCT01691898
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 completed NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT00487305
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma No drug interventions treatment 1 completed NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) No drug interventions treatment 2 recruiting NCT02819583
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies No drug interventions treatment 1 recruiting NCT03610061
A Trial of Radiotherapy and Durvalumab in DLBCL and FL No drug interventions treatment 1 completed NCT06070961
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance No drug interventions Not Available Not Available recruiting NCT02187861
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) No drug interventions treatment 2 completed NCT02451111
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma No drug interventions treatment 2 terminated NCT05389293
A Study of Mosunetuzumab in People With Follicular Lymphoma No drug interventions treatment 2 recruiting NCT01147393
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma No drug interventions treatment 1 / 2 terminated NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies No drug interventions treatment 1 recruiting NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia treatment 1 terminated NCT01796171
A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT04669171
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT06142188
Relmacabtagene Autoleucel in Hematologic Malignancies No drug interventions Not Available Not Available not_yet_recruiting NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL No drug interventions treatment 1 terminated NCT00393107
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab No drug interventions treatment 2 completed NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies No drug interventions treatment 1 / 2 completed NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT01393756
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma No drug interventions treatment 2 completed NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies No drug interventions treatment 1 terminated NCT04089215
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma No drug interventions treatment 2 active_not_recruiting NCT00880815
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant No drug interventions treatment 1 completed NCT02423837
Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma No drug interventions treatment 3 unknown_status NCT00475332
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar No drug interventions treatment 2 terminated NCT00115700
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma treatment 3 completed NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant No drug interventions supportive_care 2 completed NCT04745559
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy No drug interventions treatment 2 recruiting NCT02576275
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) No drug interventions treatment 3 withdrawn NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT04594642
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04160442
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL No drug interventions health_services_research Not Available completed NCT01078142
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT00850499
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab No drug interventions treatment 2 terminated NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases No drug interventions treatment Not Available recruiting NCT03105336
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT02316613
Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) No drug interventions Not Available Not Available completed NCT05410418
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma No drug interventions treatment 2 recruiting NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells No drug interventions Not Available Not Available recruiting NCT03600441
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 active_not_recruiting NCT05541341
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies No drug interventions Not Available Not Available recruiting NCT04468841
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma No drug interventions diagnostic 1 recruiting NCT04750941
Study of Copanlisib and Ketogenic Diet No drug interventions treatment 2 active_not_recruiting NCT04342117
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL No drug interventions Not Available Not Available terminated NCT05565417
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 / 2 recruiting NCT01282424
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 2 completed NCT05529524
Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) No drug interventions Not Available Not Available recruiting NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL No drug interventions treatment 1 / 2 active_not_recruiting NCT03297424
A Study of PLX2853 in Advanced Malignancies. No drug interventions treatment 1 completed NCT00455416
Dietary Intervention in Follicular Lymphoma No drug interventions treatment 2 unknown_status NCT05783596
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma No drug interventions treatment 2 recruiting NCT06563596
Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT05846763
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study No drug interventions Not Available Not Available recruiting NCT04246086
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT06158386
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma No drug interventions treatment 2 recruiting NCT04844086
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies No drug interventions treatment 1 terminated NCT02700022
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas No drug interventions treatment 1 terminated NCT03113422
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy No drug interventions treatment 2 completed NCT05929222
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi No drug interventions treatment 3 recruiting NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03585725
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma No drug interventions treatment 0 terminated NCT02142530
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL No drug interventions treatment 1 completed NCT02966730
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy No drug interventions treatment 0 terminated NCT00722930
Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma No drug interventions treatment 2 unknown_status NCT03828448
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma No drug interventions treatment 2 terminated NCT00774826
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma No drug interventions treatment 3 unknown_status NCT05618366
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT03525665
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression No drug interventions Not Available Not Available completed NCT04223765
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. No drug interventions treatment 1 recruiting NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 not_yet_recruiting NCT04952974
B-cell Chronic Lymphoid Malignancies Markers No drug interventions Not Available Not Available unknown_status NCT04859920
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region No drug interventions Not Available Not Available completed NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 withdrawn NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients No drug interventions prevention 2 terminated NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies treatment 2 completed NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader No drug interventions treatment 1 / 2 recruiting NCT00901927
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma No drug interventions treatment 2 terminated NCT01389076
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma No drug interventions treatment 2 terminated NCT03501576
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma No drug interventions Not Available Not Available recruiting NCT05776160
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel No drug interventions Not Available Not Available available NCT01523860
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma No drug interventions treatment 2 completed NCT01239394
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma No drug interventions treatment 2 completed NCT00136591
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma treatment 2 terminated NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT02258529
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 2 terminated NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT02631044
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) No drug interventions treatment 1 completed NCT03685344
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma No drug interventions treatment 1 terminated NCT03789240
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04918940
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma No drug interventions other Not Available completed NCT00783367
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas No drug interventions treatment 2 completed NCT06368167
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT06004167
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) No drug interventions treatment Not Available recruiting NCT00479167
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma No drug interventions treatment 2 terminated NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available recruiting NCT04722601
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma No drug interventions treatment 1 / 2 terminated NCT00859001
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy No drug interventions treatment 2 completed NCT02260804
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma No drug interventions treatment 3 completed NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors No drug interventions treatment 1 / 2 active_not_recruiting NCT00772668
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL No drug interventions treatment Not Available terminated NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 recruiting NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT00001512
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines No drug interventions treatment 1 completed NCT03498612
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases No drug interventions treatment 2 active_not_recruiting NCT00801281
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. No drug interventions treatment 3 completed NCT04048395
Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea No drug interventions Not Available Not Available unknown_status NCT02892695
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT04184414
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies No drug interventions treatment 0 unknown_status NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma No drug interventions treatment 1 terminated NCT00435955
Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma No drug interventions treatment 3 unknown_status NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies No drug interventions treatment 2 completed NCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma No drug interventions supportive_care 3 completed NCT02877550
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients No drug interventions treatment 1 completed NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies No drug interventions treatment 1 completed NCT05816850
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial No drug interventions Not Available Not Available recruiting NCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma No drug interventions treatment 2 recruiting NCT02889523
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy No drug interventions treatment 1 / 2 active_not_recruiting NCT00169208
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma No drug interventions Not Available Not Available recruiting NCT05934838
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas No drug interventions treatment 1 recruiting NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers No drug interventions treatment 3 unknown_status NCT01500538
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) No drug interventions treatment 2 terminated NCT04994587
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 recruiting NCT04590820
Oral Tazemetostat in Combination With Rituximab in R/R FL treatment 2 terminated NCT03814785
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) treatment 3 completed NCT06425302
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma No drug interventions treatment 2 recruiting NCT03921879
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma No drug interventions treatment 1 unknown_status NCT00510887
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 terminated NCT02809053
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma treatment 3 completed NCT04370405
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma No drug interventions treatment 2 unknown_status NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL No drug interventions treatment 1 / 2 completed NCT02162771
To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan treatment 3 completed NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT00319332
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen No drug interventions treatment 3 withdrawn NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies treatment 1 terminated NCT02376699
Safety Study of SEA-CD40 in Cancer Patients treatment 1 terminated NCT01609036
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma No drug interventions Not Available Not Available terminated NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). No drug interventions treatment 1 / 2 recruiting NCT03057418
Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim No drug interventions treatment 1 completed NCT01077518
Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy treatment 3 terminated NCT03310619
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies treatment 1 / 2 completed NCT01584141
Study of Lymphoma in Asia No drug interventions Not Available Not Available completed NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) treatment 1 completed NCT01164696
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin Not Available Not Available completed NCT00915096
Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma No drug interventions Not Available Not Available completed NCT02278796
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) No drug interventions treatment 2 completed NCT05228158
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan Not Available Not Available recruiting NCT01786135
A Safety Study of SGN-CD19A for B-Cell Lymphoma treatment 1 completed NCT06290622
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL treatment 1 withdrawn NCT05616325
Long-term Ovarian Fertility in Patients Treated for Lymphoma. No drug interventions Not Available Not Available not_yet_recruiting NCT04036448
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea Not Available Not Available completed NCT00092274
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma treatment 1 / 2 withdrawn NCT03357627
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma other 1 completed NCT00864227
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) No drug interventions treatment 2 completed NCT02086591
A Phase II Study of Doxycycline in Relapsed NHL treatment 2 terminated NCT01902862
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma treatment 2 terminated NCT02743546
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma No drug interventions treatment 1 withdrawn NCT00930514
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma No drug interventions treatment 1 completed NCT01250223
Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) No drug interventions Not Available Not Available completed NCT00308087
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma No drug interventions treatment 2 terminated NCT02631577
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 1 / 2 completed NCT00849147
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) No drug interventions treatment 2 completed NCT00060671
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma treatment 3 terminated NCT04982471
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study No drug interventions Not Available Not Available recruiting NCT04735471
A Phase 1 Study of ADI-001 in B Cell Malignancies No drug interventions treatment 1 recruiting NCT04911478
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells No drug interventions Not Available Not Available enrolling_by_invitation NCT00081809
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma treatment 2 completed NCT02472756
A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma No drug interventions Not Available Not Available completed NCT00427856
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) No drug interventions treatment 2 completed NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) No drug interventions prevention 2 completed NCT02257242
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma No drug interventions treatment 1 completed NCT02343536
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma No drug interventions treatment 1 completed NCT00394836
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab No drug interventions treatment 2 completed NCT01263418
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas No drug interventions treatment 2 withdrawn NCT02569996
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma No drug interventions treatment 3 completed NCT03682796
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma No drug interventions treatment 1 completed NCT00317096
FCM Versus R-FCM Followed by R-Maintenance or Observation Only No drug interventions treatment 3 unknown_status NCT01208896
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma No drug interventions treatment 2 completed NCT05849857
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries No drug interventions treatment 2 recruiting NCT01234766
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma No drug interventions treatment 2 completed NCT00562965
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) No drug interventions health_services_research 3 terminated NCT00315731
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine No drug interventions treatment 1 active_not_recruiting NCT01950273
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma No drug interventions treatment 1 completed NCT00494780
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients No drug interventions treatment 2 completed NCT03087929
Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon No drug interventions Not Available Not Available completed NCT02413489
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma No drug interventions treatment 2 terminated NCT00193492
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT05106192
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. No drug interventions supportive_care Not Available not_yet_recruiting NCT00475644
A Study of Enzastaurin in Participants With Follicular Lymphoma No drug interventions treatment 2 completed NCT01307267
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab No drug interventions treatment 1 completed NCT03934567
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma No drug interventions treatment 2 recruiting NCT02390869
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients No drug interventions treatment 3 active_not_recruiting NCT06045910
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT01022255
Autologous Vaccine for Follicular Lymphoma No drug interventions treatment 1 completed NCT06097364
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma No drug interventions treatment 3 recruiting NCT06091254
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma treatment 3 recruiting NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT03768505
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) treatment 2 terminated NCT06526793
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL No drug interventions treatment 2 not_yet_recruiting NCT04537715
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels treatment 1 completed NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT04745832
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) treatment 3 terminated NCT04049513
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) treatment 1 active_not_recruiting NCT03265158
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 No drug interventions Not Available Not Available unknown_status NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT05409066
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma treatment 3 recruiting NCT04767308
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies No drug interventions treatment 0 unknown_status NCT03460977
Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma No drug interventions treatment 1 recruiting NCT03571828
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma No drug interventions treatment 1 terminated NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms No drug interventions Not Available Not Available recruiting NCT05888493
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma No drug interventions treatment 3 recruiting NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT03869619
REal World Data in LYmphoma and Survival in Adults No drug interventions Not Available Not Available recruiting NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT02875548
A Study to Assess the Long-term Safety of Tazemetostat No drug interventions treatment 1 / 2 enrolling_by_invitation NCT06191744
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma No drug interventions treatment 3 recruiting NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma No drug interventions treatment 1 terminated